Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Inspire Medical Systems, Inc.

INSP

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.

Last trade $58.87
Day change -$0.25 (-0.42%)
Day range $57.85 – $59.31
Volume 220,905
Market cap $1.71B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.71B
Price / earnings
17×
Price / book
2.07×
Price / sales
1.94×
EV / sales
1.73×
EV / EBITDA
44.19×

Profitability

Earnings per share
$3.48
Return on assets
10.57%
Return on equity
12.18%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.45×
Quick ratio
4.61×
Cash ratio
1.96×

Cash flow

Price / cash flow
12.69×
Price / free cash flow
17.49×
Free cash flow
$97.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for INSP, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$206.7M$200.58M$204.58M$269.08M$224.5M$217.09M$201.32M$239.72M
Cost of revenue$28.84M$29.12M$27.67M$36.07M$31.77M$34.67M$30.71M$35.99M
Gross profit$177.86M$171.46M$176.91M$233.01M$192.73M$182.41M$170.61M$203.73M
Selling, general and administrative$184.4M$147.28M$152.2M$161.95M$158.87M$159.52M$144.29M$141.51M
Research and development$22.18M$24.7M$25.83M$24.94M$24.21M$26.21M$27.8M$30.34M
Total operating expenses$206.57M$171.97M$178.03M$186.9M$183.08M$185.73M$172.09M$171.85M
Operating income-$28.72M-$514K-$1.12M$46.11M$9.64M-$3.32M-$1.49M$31.88M
Interest expense$0$0$0-$122K$0$0$0-$22K
Income before taxes-$25.01M$3.12M$2.4M$50.32M$13.55M-$2.33M$4.16M$36.64M
Income taxes-$616K$2.8M$13.69M-$85.77M$3.62M$1.26M$1.17M$1.41M
Net income-$24.39M$314K-$11.29M$136.09M$9.93M-$3.59M$2.99M$35.22M
Net income attributable to common shareholders-$24.39M$314K-$11.29M$136.09M$9.93M-$3.59M$2.99M$35.22M
EBITDA-$23.58M$4.08M$3.99M$49.93M$13.32M$98K$1.56M$34.36M
Basic earnings per share-$0.84$0.01-$0.39$4.70$0.34-$0.12$0.10$1.18
Diluted earnings per share-$0.84$0.01-$0.39$4.60$0.34-$0.12$0.10$1.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's Why You Should Retain INSP Stock in Your Portfolio for Now

Inspire Medical Systems (INSP) is positioned for solid growth despite a 32.5% year-to-date stock decline. The company faces near-term headwinds from $120 million in annual coding and reimbursement disruptions, but benefits from strong Inspire V adoption, improved clinical evidence, and a new CPT code effective in 2028. Project Horizon initiatives are expected to support low-single-digit revenue growth in 2027, though GLP-1 adoption and international weakness remain concerns.

Zacks Investment Research

INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

Inspire Medical Systems (INSP) shares gained 12.1% over three months despite a 7.9% revenue decline and 62.2% drop in adjusted Q3 EPS. Reimbursement issues cost the company $30M in Q3 revenues with a projected $120M full-year 2026 impact. The company targets low-single-digit revenue growth in 2027 through Project Horizon and battery replacement procedures, though reimbursement execution remains a key risk factor.

Zacks Investment Research

Inspire Medical Systems (INSP) Q3 Earnings and Revenues Beat Estimates

Inspire Medical Systems beat Q3 earnings expectations with $0.14 EPS versus consensus of $0.10, and revenues of $206.7M slightly above estimates. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The stock has underperformed the S&P 500 by 37% year-to-date, and near-term underperformance is expected despite the positive earnings surprise.

Zacks Investment Research

Here's What Key Metrics Tell Us About Inspire (INSP) Q3 Earnings

Inspire Medical Systems (INSP) reported Q3 2026 revenue of $206.7 million, down 7.9% year-over-year, though it beat consensus estimates by 1.17%. EPS of $0.14 significantly exceeded expectations of $0.10 (+40%), but declined from $0.38 a year ago. U.S. revenue fell 7.9% to $197.49 million, while international revenue declined 8.9% to $9.21 million. The stock has been assigned a Zacks Rank #4 (Sell) rating.

Zacks Investment Research

INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?

Inspire Medical Systems (INSP) shares gained 47.8% over three months as reimbursement uncertainty eases following new CPT code approvals and better-than-expected Q2 results. The company reported $200.6M in revenues and 14 cents adjusted EPS, while Project Horizon aims to redirect $30M in annualized savings toward growth initiatives. However, near-term sales remain disrupted and full execution risks persist.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.